国常会通过条例，促进生物医药产业提质升级

Group 1 - The State Council of China, led by Premier Li Qiang, has approved the draft regulations for the management of clinical research and clinical application of biomedical new technologies, aiming to promote innovation and accelerate the transformation of technology and results in the biomedical industry [1] - The Chinese biomedical industry is in a critical phase of rapid development, with the market size expected to exceed 3.5 trillion yuan by 2025, accounting for over 10% of the global biomedical market, positioning China as the second-largest innovative drug market globally [1] - Technological innovation is driving transformation, with AI expected to shorten drug development cycles by over 30% and increase target discovery efficiency by 30 times, with AI-designed drugs projected to account for over 15% of approved new drugs by 2028 [1] Group 2 - The approval cycle for innovative drugs has been shortened to 6-8 months, supported by dynamic adjustments to the medical insurance catalog, with a projected 35% year-on-year increase in IPO fundraising in the biomedical sector for 2024 [2] - The Chinese biomedical industry is shifting from "scale expansion" to "value creation," with innovation drugs, gene therapy, and AI pharmaceuticals identified as core growth engines driven by policy, technology, and capital [2] - Key A-share related stocks include Huahai Pharmaceutical and Kexing Pharmaceutical, indicating potential investment opportunities in the sector [2]